The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study.
Adrian G. Sacher
No relevant relationships to disclose
Humberto Lara-Guerra
No relevant relationships to disclose
Thomas K. Waddell
Research Funding - Roche
Lucia Kim
No relevant relationships to disclose
Zhuo Chen
No relevant relationships to disclose
Alexandra Salvarrey
No relevant relationships to disclose
Gail Darling
No relevant relationships to disclose
Kazuhiro Yasufuku
No relevant relationships to disclose
Shaf Keshavjee
No relevant relationships to disclose
Marc de Perrot
No relevant relationships to disclose
Frances A. Shepherd
Consultant or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Recombio; Roche
Stock Ownership - Lilly; Pfizer
Honoraria - GlaxoSmithKline; Lilly; Roche
Expert Testimony - AstraZeneca
Geoffrey Liu
No relevant relationships to disclose
Ming Sound Tsao
No relevant relationships to disclose
Natasha B. Leighl
Research Funding - Roche